Plain-English translation of NCT07433673 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a drug that helps your immune system fight cancer—works better when combined with three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) for people with bile duct cancer that cannot be surgically removed. Researchers have seen that each of these treatments works against advanced bile duct cancer separately, but this is the first time all four are being tested together. The goal is to shrink tumors enough that surgery becomes possible, which is the best chance for a cure.
Surgery is currently the only way to potentially cure bile duct cancer, but many patients are diagnosed when their tumors are too advanced or spread too widely to operate on. This trial exists to find a way to shrink these inoperable tumors so that surgery becomes an option—giving patients a real chance at long-term survival.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous chemotherapy along with the immune-boosting medication on a regular treatment schedule. Throughout the trial, you will have frequent blood tests and imaging scans (CT or MRI) to monitor how well the treatment is working and to watch for side effects. The goal is to shrink your tumor over time so that your surgical team can evaluate whether an operation becomes possible. Regular visits with your cancer doctor will track your progress and manage any side effects that develop.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Columbia University
Collaborators
Regeneron Pharmaceuticals
Enrollment target
~20 participants
Started
August 2026
Primary completion
January 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Research Nurse Navigator
Columbia University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.